Stock IMM IMMUTEP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Immutep Limited

Equities

IMM

AU000000IMM6

Market Closed - Australian S.E.
Other stock markets
 02:10:15 2024-05-22 am EDT 		5-day change 1st Jan Change
0.475 AUD +1.06% Intraday chart for Immutep Limited +5.56% +37.68%
May. 17 Capital One Initiates Immutep at Overweight Rating With $10 Price Target MT
May. 15 Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Capital One Initiates Immutep at Overweight Rating With $10 Price Target
MT
Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data
MT
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
AQ
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024
CI
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
AQ
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
CI
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial
MT
Immutep Limited Provides an Update on the Ongoing Development of its Product Candidates, eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2024
CI
Canaccord Starts Immutep at Buy, Price Target is AU$1.00
MT
Immutep Quarterly Activities Report Q3 FY24
AQ
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
CI
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck
MT
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
CI
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
AQ
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761
CI
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)
PU
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial
MT
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76
PU
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
AQ
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMM Stock
  4. News Immutep Limited
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW